🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 14 of 114

  1. BI 764198

    Boehringer Ingelheim

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    1 trial

  2. BI 764198, Placebo matching BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  3. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  4. BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828

    Boehringer Ingelheim

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  5. BIIB019 (Daclizumab)

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  6. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  7. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  8. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  9. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  10. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

    Biogen

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  11. BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

    Biogen

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  12. BIIB111

    Biogen

    Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

    phase 3 small molecule active

    1 trial

  13. BIIB122

    Denali Therapeutics

    Parkinson Disease

    phase 3 small molecule active

    2 trials

  14. BIOTIN, Medebiotin Fuerte solución inyectable, Medebiotín Fuerte Comprimidos

    The George Institute

    Metilcrotonilglicinuria, biotinidasa deficit

    phase 3 small molecule active

    1 trial

  15. BIPAP Synchrony

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 other completed

    1 trial

  16. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  17. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  18. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA (Morquio A Syndrome)

    phase 3 small molecule completed

    1 trial

  19. BMN 110 - Weekly

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IV A

    phase 3 small molecule completed

    1 trial

  20. BMN 110 Weekly

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 3 small molecule completed

    1 trial

  21. BMN 111

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    6 trials

  22. BMN 165

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 3 small molecule completed

    1 trial

  23. BMN 333

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  24. BMN 333, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection, BMN 333

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  25. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Late-onset Pompe Disease

    phase 3 small molecule terminated

    1 trial

  26. BMN165 20mg/day

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule completed

    1 trial

  27. BMS-986353

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis

    phase 3 small molecule active

    1 trial

  28. BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech SE

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  29. BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  30. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers Squibb Australia Pty Ltd

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  31. BOTOX

    AbbVie

    Masseter Muscle Prominence

    phase 3 small molecule completed

    1 trial

  32. BOTOX 50 UNITÉS ALLERGAN, poudre pour solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 small molecule active

    1 trial

  33. BRUKINSA 80 mg hard capsules, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, IMBRUVICA 140 mg hard capsules, Lisaftoclax, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  34. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  35. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  36. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  37. BXCL501

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    4 trials

  38. BXCL501

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 3 small molecule completed

    1 trial

  39. BYL719, BYL719, Placebo to BYL719 125 mg film-coated tablets, Placebo to BYL719 200 mg film-coated tablets, Placebo to BYL719 50 mg film-coated tablets, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  40. Bacillus Calmette Guerin and interferon alpha

    Hospital Authority, Hong Kong

    Carcinoma of Urinary Bladder, Superficial

    phase 3 small molecule completed

    1 trial

  41. BaidI Quzhi granule

    Universal Integrated

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  42. Balcinrenone+Dapagliflozin, Balcinrenone+Dapagliflozin, Forxiga, Balcinrenone+Dapagliflozin, Forxiga 10 mg film-coated tablets

    AstraZeneca AB

    Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death

    phase 3 small molecule active

    1 trial

  43. Baloxavir Marboxil

    Hoffmann-La Roche

    Influenza

    phase 3 small molecule completed

    1 trial

  44. Balugrastim

    Teva Pharma GmbH

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  45. Bardoxolone methyl

    Biogen

    Pulmonary Hypertension

    phase 3 small molecule terminated

    1 trial

  46. Baricitinib

    Eli Lilly and Company

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  47. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

  48. Baricitinib

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.